DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 20-919/S-022

Pfizer, Inc.
Attention: Mary Boylan-Bost, Associate Director, Worldwide Regulatory Strategy
235 East 42nd Street
New York, NY 10017

Dear Ms. Boylan-Bost:

Please refer to your supplemental new drug application dated August 21, 2008, received August 21, 2008, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Geodon (ziprasidone meyslate) Injection, 20 mg/mL.

This "Prior Approval" supplemental new drug application provides for an alternate manufacturing and stability testing site for the drug product.

We completed our review of this supplemental new drug application and it is approved.

We remind you that you must comply with the reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Teshara G. Bouie, Regulatory Health Project Manager, at (301) 796-1649.

Sincerely,

{See appended electronic signature page}

James D. Vidra, Ph.D.
Branch Chief
Branch VII, Division of Post-Marketing Evaluation
Office of New Drug Quality Assessment
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Jim Vidra

12/19/2008 09:49:16 AM